Literature DB >> 12171712

Highly efficient retroviral gene transfer into immortalized CD34(-) cells and organ distribution after transplantation into NOD/SCID mice.

K Thalmeier1, R Huss.   

Abstract

BACKGROUND: CD34(-) stem cells are apparently the earliest progenitors of hematopoiesis and mesenchymal tissues. The majority of those progeny rests in the BM as fibroblast-like cells, but can also circulate the peripheral blood. Nevertheless, CD34(-), fibroblast-like cells can be isolated from BM aspirates and PBMC, mediated by their ability to adhere to the plastic surface of tissue culture flasks. In standard colony assays, CD34(-), fibroblast-like cells produce a significant number of colony-forming-units (CFUs), mainly CFU-F (fibroblast).
METHODS: Despite advanced cell-culture techniques and the application of various growth factors, the life span of those multipotent stem cells is limited. Therefore, we immortalized and cloned fibroblast-like, CD34(-) stem cells and used retroviral constructs containing the green-fluorescence protein (GFP) to determine the gene-transfer efficiency and their use for gene marking prior to transplantation into NOD/SCID mice.
RESULTS: We could demonstrate a highly efficient retroviral gene transfer into those immortalized CD34(-), fibroblast-like hematopoietic cells (up to 95% transduced cells), maintaining their ability to produce CFUs, as well as a distinct organ distribution after transplantation into the recipient animals, functioning as SCID-repopulating cells (SRC). Transplanted cells could be detected in the BM, as well as other parenchymal organs, such as the lung, liver, skin, small intestine and brain. DISCUSSION: CD34(-), fibroblast-like progenitor cells can give rise to hematopoietic progeny, but also home to mesenchymal organ sites in recipient animals. There is increasing evidence that pluripotent CD34(-) stem cells can be isolated from various sources and still maintain their capabilities to generate progeny of different tissues. This could be a promising approach to using peripheral-blood derived stem cells for cellreplacement therapy and tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12171712     DOI: 10.1080/146532401317070871

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  5 in total

1.  Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.

Authors:  Kerstin Knoop; Marie Kolokythas; Kathrin Klutz; Michael J Willhauck; Nathalie Wunderlich; Dan Draganovici; Christian Zach; Franz-Josef Gildehaus; Guido Böning; Burkhard Göke; Ernst Wagner; Peter J Nelson; Christine Spitzweg
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

2.  Co-transplantation of human mesenchymal stem cells promotes human CD34+ cells engraftment in a dose-dependent fashion in NOD/SCID mice.

Authors:  Seong-Kyu Park; Jong-Ho Won; Hyun-Jung Kim; Sang-Byung Bae; Chan-Kyu Kim; Kyu-Taeg Lee; Nam-Su Lee; You Kyoung Lee; Dae-Chul Jeong; Nak-Gyun Chung; Hyun-Soo Kim; Dae-Sik Hong; Hee-Sook Park
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

Review 3.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

4.  Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment.

Authors:  Stephan Fricke; Manuela Ackermann; Alexandra Stolzing; Christoph Schimmelpfennig; Nadja Hilger; Jutta Jahns; Guido Hildebrandt; Frank Emmrich; Peter Ruschpler; Claudia Pösel; Manja Kamprad; Ulrich Sack
Journal:  PLoS One       Date:  2009-07-07       Impact factor: 3.240

5.  Bone marrow-derived mesenchymal stem cells migrate to healthy and damaged salivary glands following stem cell infusion.

Authors:  Silke Schwarz; Ralf Huss; Michaela Schulz-Siegmund; Breda Vogel; Sven Brandau; Stephan Lang; Nicole Rotter
Journal:  Int J Oral Sci       Date:  2014-05-09       Impact factor: 6.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.